Tech Company Financing Transactions
Ambit Biosciences Funding Round
On 11/14/2007, Ambit Biosciences received $49.3 million in Series D funding from Applied Ventures, Avalon Ventures and Forward Ventures.
Transaction Overview
Company Name
Announced On
11/14/2007
Transaction Type
Venture Equity
Amount
$49,300,000
Round
Series D
Investors
Proceeds Purpose
The Series D funds will be used to support continued advancement of Ambit's growing product pipeline, which includes several drug candidates in clinical and pre-clinical development.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
11080 Roselle St.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Ambit Biosciences is a biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for the treatment of cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Martino
Chief Financial Officer
Alan Fuhrman
Chief Medical Officer
Athena Countouriotis
Browse more venture capital transactions:
Prev: 11/14/2007: Silicon Clocks venture capital transaction
Next: 11/14/2007: OpenPages venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to document all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs